Monoclonal Antibodies
INBRX-109 for Chondrosarcoma
This trial tests INBRX-109, a specially designed protein, in patients with a hard-to-treat type of bone cancer. The treatment helps the immune system target and kill cancer cells by attaching to a specific marker on these cells.
Monoclonal Antibodies
Aplitibart for Metastatic Colorectal Cancer
This trial is testing a new drug called aplitibart with standard chemotherapy and another drug in patients with metastatic colorectal cancer that has come back or spread. The treatment works by killing cancer cells and cutting off their nutrient supply.
Popular Filters
Trials for Bone Cancer Patients
Histone Methyltransferase Inhibitor
Seclidemstat + Chemotherapy for Ewing Sarcoma
This trial tests seclidemstat alone and with other drugs in patients with specific types of sarcoma, especially those who haven't responded to other treatments. The treatment aims to block cancer growth and use chemotherapy to kill cancer cells.
CAR T-cell Therapy
TIL Therapy for Cancer
This trial tests a treatment using a patient's own immune cells to fight various cancers that haven't responded to other treatments or have come back. The immune cells are taken from the tumor, grown in a lab, and then reintroduced into the body to target and kill cancer cells. The study aims to see how well this approach works and how safe it is.
Seclidemstat Access for Sarcoma
This trial allows patients who have previously benefited from seclidemstat to continue their treatment. Seclidemstat is a drug that aims to stop cancer cells from growing by blocking essential proteins. The trial targets patients who are still seeing positive results.
Trials for Cancer Patients
Glutaminase Inhibitor
IACS-6274 +/− Bevacizumab/Paclitaxel for Cancer
This trial is testing a new drug to see if it's safe and effective in treating patients with advanced solid tumors. The new drug, IACS-6274, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving IACS-6274 with or without pembrolizumab may help to control the disease.
Virus Therapy
AdAPT-001 for Cancer
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
CAR T-cell Therapy
TIL Therapy for Cancer
This trial tests a treatment using a patient's own immune cells to fight various cancers that haven't responded to other treatments or have come back. The immune cells are taken from the tumor, grown in a lab, and then reintroduced into the body to target and kill cancer cells. The study aims to see how well this approach works and how safe it is.
Trials With No Placebo
Glutaminase Inhibitor
IACS-6274 +/− Bevacizumab/Paclitaxel for Cancer
This trial is testing a new drug to see if it's safe and effective in treating patients with advanced solid tumors. The new drug, IACS-6274, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving IACS-6274 with or without pembrolizumab may help to control the disease.
Virus Therapy
AdAPT-001 for Cancer
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
View More Related Trials
Frequently Asked Questions
Introduction to chondrosarcoma
What are the top hospitals conducting chondrosarcoma research?
In the realm of clinical trials targeting chondrosarcoma, several top hospitals have emerged as beacons of hope for patients. Among them is Memorial Sloan Kettering Cancer Center in New York, which currently leads the pack with six active trials focused on this rare form of bone cancer. Having recorded its first chondrosarcoma trial in 2018, Memorial Sloan Kettering's dedication to finding effective treatments is evident. MD Anderson Cancer Center in Houston joins the ranks with five ongoing chondrosarcoma trials and a history that dates back to their inaugural study in 2006. Not far behind is the Sarcoma Oncology Center located amidst sunny Santa Monica, California. This center boasts four active clinical trials for chondrosarcoma and began its journey towards combating this condition in 2007.
Houston's M D Anderson Cancer Center remains steadfastly committed to fighting against this malignancy as well, seeking innovative solutions through three current chondrosarcoma trials since recording their first investigation also around 2007.Boston's Massachusetts General Hospital rounds out this list by offering three active clinical studies regarding chondrosarcoma while having embarked on their exploration into this cancer type as early as1999.
Chondrosarcoma presents unique challenges due to its rarity and complexity; however, these leading hospitals' unwavering commitment showcases the progress being made in understanding and treating this disease. Collaborative efforts across institutions provide invaluable opportunities for patients affected by chondrosarcoma, inching closer towards improved outcomes and ultimately a brighter future for those diagnosed with this challenging condition
Which are the best cities for chondrosarcoma clinical trials?
When it comes to chondrosarcoma clinical trials, several cities emerge as prime hubs for research and development. Houston, Texas leads the pack with 13 active trials investigating treatments such as AG-120, INBRX-109, and Proton Beam Therapy. Following closely behind are Los Angeles, California and New york, New York, both with 11 ongoing studies focusing on therapies like Doxorubicin, LY3410738, and INBRX-109. Chicago, Illinois also shows promise with 10 active trials examining options such as Doxorubicin and LY3410738. Lastly, Boston,Masachusetts offers hope with 8 ongoing studies exploring treatments like LY3410738and AG-120.In these cities across the United States,chondrosarcoma patients have access to cutting-edge clinical trials that may pave the way for improved treatment outcomes.It's important to consult medical professionals for specific recommendations tailored to individual cases.
Which are the top treatments for chondrosarcoma being explored in clinical trials?
Exciting progress is being made in clinical trials for chondrosarcoma, with several top treatments showing promise. AG-120 has emerged as a frontrunner, currently undergoing two active trials and contributing to the total of two all-time chondrosarcoma trials since its listing in 2014. Another contender capturing attention is INBRX-109, involved in two ongoing trials and adding to the tally of two all-time chondrosarcoma studies since 2018. Equally significant is seclidemstat, also participating in two current trials and entering the field in 2018. Lastly, an intriguing newcomer on the scene is CD30 biAb-AATC—a cutting-edge treatment that recently commenced one active trial after its first listing just this year (2022). These advancements mark important strides towards improved therapies for individuals battling chondrosarcoma.
What are the most recent clinical trials for chondrosarcoma?
Recent clinical trials offer hope and potential advancements in the treatment of chondrosarcoma, a rare form of bone cancer. One trial focuses on an experimental therapy called anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC). This innovative approach combines targeted antibodies with activated immune cells to attack cancer cells specifically. Another trial investigates the efficacy of YH001 combined with Envafolimab, aiming to determine the recommended dose for treating chondrosarcoma subtype 1. Additionally, Seclidemstat is being evaluated as a potential therapeutic option for this aggressive tumor type. These studies provide valuable insights into new treatment avenues that may improve outcomes for individuals battling chondrosarcoma.
What chondrosarcoma clinical trials were recently completed?
A recent milestone has been reached in the field of chondrosarcoma research, with the completion of a clinical trial investigating FT-2102. Conducted by Forma Therapeutics, Inc., this trial concluded in November 2018. This significant endeavor contributes valuable insights to our understanding and treatment approaches for chondrosarcoma, highlighting the ongoing efforts to improve outcomes for patients affected by this challenging condition.